Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

Author's Avatar
Jan 10, 2023

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022.